Viamet Pharmaceuticals

66 articles about Viamet Pharmaceuticals

• PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertension

  1/13/2020

  PhaseBio to be responsible for all development, manufacturing and commercialization

• NovaQuest Capital Management to Acquire Viamet Pharmaceuticals and the VT-1161 Antifungal Program

  1/3/2018

  Upon closing of the acquisition, Viamet Pharmaceuticals will be a portfolio company of NovaQuest Capital, which will focus on further development of VT-1161 and related assets.

• Phase IIb Results Of Viamet’s Oral VT-1161 For The Treatment Of Recurrent Vulvovaginal Candidiasis Presented At IDSOG Annual Meeting

  8/11/2017

• Viamet Release: Data On VT-1161 For The Treatment Of RVVC To Be Presented At The Infectious Diseases Society For Obstetrics And Gynecology Annual Meeting

  8/8/2017

• Viamet To Present Data On VT-1161 For The Treatment Of Onychomycosis At The American Podiatric Medical Association Annual Meeting

  7/27/2017

• Viamet Release: FDA Grants Fast Track Designation To VT-1598 For Treatment Of Valley Fever

  7/13/2017

• Viamet To Present Data On VT-1161 For The Treatment Of Onychomycosis At The 4th International Summit On Nail Diseases

  6/21/2017

• Viamet To Participate In Antifungal Panel Discussion At The 2017 BIO International Convention

  6/14/2017

• Viamet’s VT-1598 Demonstrates Potent Activity Against Candida Auris And Other Life-Threatening Fungal Species

  6/5/2017

• Viamet Presents Phase IIb Results Demonstrating Unprecedented Efficacy Of Oral VT-1161 In The Treatment Of Recurrent Vulvovaginal Candidiasis

  6/5/2017

• Viamet Data For VT-1161 And VT-1598 To Be Presented At American Society of Microbiology’s ASM Microbe 2017 Conference

  6/5/2017

• Viamet Data For VT-1161 And VT-1598 To Be Presented At American Society for Microbiology’s ASM Microbe 2017 Conference

  5/17/2017

• Viamet Presents Positive Results From Phase IIb Trial Of VT-1161 In Onychomycosis At American Academy of Dermatology Annual Meeting

  3/6/2017

• Viamet Announces RENOVATE Phase IIb Onychomycosis Results To Be Presented At American Academy of Dermatology 2017 Annual Meeting

  3/1/2017

• Viamet Reports Positive Results From REVIVE Phase 2b Trial Of Oral VT-1161 In Recurrent Vulvovaginal Candidiasis

  1/6/2017

• Viamet Reports Positive Results From RENOVATE Phase 2b Trial Of Oral VT-1161 In Onychomycosis

  1/6/2017

• Viamet Release:FDA Grants QIDP and Fast Track Designations to VT-1161 for Treatment of Recurrent Vulvovaginal Candidiasis

  10/12/2016

• Viamet To Present At The 25th European Academy Of Dermatology And Venereology Congress

  9/27/2016

• Viamet To Present At The 2016 Mycoses Study Group Education And Research Consortium (MSGERC) Conference

  9/19/2016

• Viamet Release: FDA Grants QIDP Designation To VT-1598 For Treatment Of Valley Fever

  9/15/2016